Matthew Logan

Matthew Logan has a diverse work experience in the scientific field. Matthew currently holds the position of Principal Scientist at Vividion Therapeutics Inc. starting in 2023. Prior to that, they served as a Principal Scientist and then Senior Scientist at Neurocrine Biosciences from 2021 to 2023. Matthew also worked at Gilead Sciences from 2015 to 2021, where they held the positions of Senior Research Scientist and Research Scientist. Before that, they pursued their Ph.D. at Stanford University from 2010 to 2015, focusing on the synthesis and analysis of batrachotoxin and its analogues. Matthew's previous experience includes working as an Undergraduate Researcher at Albion College and as an NSF REU researcher at California State University, Fullerton, both in 2008.

Matthew Logan received their Bachelor of Arts degree in Chemistry from Albion College from 2006 to 2010. Matthew then pursued a PhD in Organic Chemistry at Stanford University from 2010 to 2015.